Rotavirus gastroenteritis hospitalizations in provinces with different vaccination coverage rates in Spain, 2013–2018

J. Ruiz-Contreras1, S. Alfayate-Miguelez2, B. Carazo-Gallego3, E. Onís4, L. Díaz-Munilla5, M. Mendizabal5, M. Méndez Hernández6, B. Ferrer-Lorente7, M. Unsain-Mancisidor8, J. T. Ramos-Amador9, B. Croche-Santander10, F. Centeno Malfaz11, J. Rodriguez-Suárez12, M. Cotarelo13, M. San-Martín13* and J. Arístegui4

Abstract
Background: Rotavirus (RV) vaccines are available in Spain since 2006 but are not included in the National Immunization Program. RV vaccination has reached an intermediate vaccination coverage rate (VCR) but with substantial differences between provinces. The aim of this study was to assess the ratio of RV gastroenteritis (RVGE) admissions to all-cause hospitalizations in children under 5 years of age in areas with different VCR.

Methods: Observational, multicenter, cross-sectional, medical record-based study. All children admitted to the study hospitals with a RVGE confirmed diagnosis during a 5-year period were selected. The annual ratio of RVGE to the total number of all-cause hospitalizations in children < 5 years of age were calculated. The proportion of RVGE hospitalizations were compared in areas with low (< 30%), intermediate (31–59%) and high (> 60%) VCR.

Results: From June 2013 to May 2018, data from 1731 RVGE hospitalizations (16.47% of which were nosocomial) were collected from the 12 study hospitals. RVGE hospital admissions accounted for 2.82% (95 CI 2.72–3.00) and 43.84% (95% CI 40.53–47.21) of all-cause and Acute Gastroenteritis (AGE) hospitalizations in children under 5 years of age, respectively. The likelihood of hospitalization due to RVGE was 56% (IC95%, 51–61%) and 27% (IC95%, 18–35%) lower in areas with high and intermediate VCR, respectively, compared to the low VCR areas.

Conclusions: RVGE hospitalization ratios are highly dependent on the RV VCR. Increasing VCR in areas with intermediate and low coverage rates would significantly reduce the severe burden of RVGE that requires hospital management in Spain.

Clinical trial registration Not applicable

Keywords: Rotavirus, Acute Gastroenteritis, Hospitalization, Vaccination coverage rate, Spain

Background
Rotavirus (RV) infection is a significant cause of hospitalization [1] in children, and is associated with an important consumption of health care resources [2, 3] representing a significant clinical and economic burden for the health care system in developed countries [4, 5]. RV has also been found to be a major etiologic agent for pediatric nosocomial AGE [6].

Before the availability of vaccines, RV was the leading cause of severe gastroenteritis in children < 5 year of age worldwide [1]. In Europe, it was estimated that every year RV accounted for 231 deaths, over 87,000 hospitalizations and almost 700,000 outpatients’ visits. A systematic
review had confirmed the significant public health benefit of RV vaccination in Europe [2, 7]. Since 2009, World Health Organization Strategic Advisory Group of Experts (SAGE), recommended that all national immunization programs include RV vaccination for infants [8–10].

Two rotavirus vaccines have been available in Spain since 2006: RotaTeq®, (RV5; MSD) [11] and Rotarix®, (RV1; GSK) [12], but not included in the National Immunization Program. They are used under pediatricians’ recommendations and paid in full by parents, leading to an intermediate level of vaccination coverage and substantial differences between provinces [3, 13–19]. Both vaccines are indicated for immunization of infants from 6 weeks of age and the schedule must be completed before 24 or 32 weeks of age for Rotarix and RotaTeq, respectively. Because of the incidental finding of circovirus DNA contamination in both vaccines, the Spanish Medicine Agency suspended RV vaccine distribution temporarily, withdrawing RV5 from June 2010 to November 2010, and RV1 from February 2010 to June 2016 [13]. Since reintroduction after the 5 months suspension, VCR has steadily increased from 19% in 2010 to 52% in 2018.

Previous studies in Spain reported RVGE-related hospitalization rates that ranged between 120 and 480 cases per 100,000 children < 5 years of age [20–24]. This variability may be explained by some study-related factors, such as the selected populations, the observed study periods, and other methodological issues. Most of these studies are based on data collected from hospital administrative databases, which includes diagnostic information codified using the International Classification of Diseases (ICD) codes. The reliability of the estimation of burden of hospital-based disease depends, therefore, on the quality of codification. It has been stated that the use of hospital discharge databases frequently underestimate the incidence of RVGE-related hospitalizations, as a proportion of RV cases admitted to hospital is not coded as RVGE in the hospital discharge databases [13, 15–17, 21–25].

The objective of the present study was to estimate the annual ratio of RVGE hospitalizations among children under 5 years of age and to assess the differences in RVGE hospitalizations between areas with different VCR in Spain.

**Methods**

**Study design**

This was an observational, multicenter, cross-sectional study performed at the pediatric and microbiology departments of hospitals from provinces with different RV VCR in Spain. The VCR was estimated based on the number of RV vaccine doses distributed, provided by IQVIA (formerly IMS Health), and the number of newborns each year in the different provinces, obtained from the official census.

According to the VCR observed in the different provinces of Spain (ranging from 10 to 75%, approximately), three study groups were defined: low (≤ 30%), intermediate (31–59%), and high (≥ 60%) VCR (Fig. 1).

Hospitals that performed systematic detection of RV in all children <5 years admitted for AGE and with electronic records in the Pediatric and Microbiology Departments were considered for inclusion. The pediatric population (≤ 14 years of age) of each participating hospital was collected from hospital databases.

**Ethics**

The study was designed, conducted and reported in accordance with the Guidelines for Good Pharmacoepidemiology Practices of the International Society for Pharmacoepidemiology [26], with the ethical principles of the Declaration of Helsinki, and with the current Spanish legislation related to observational studies (Ministerial Order SAS/3470/2009) [27]. The study was reviewed and approved by the Clinical Research Ethics Committee of the Basque Country in Txagorritxu Hospital (Vitoria, Spain).

**Study population**

All children <5 years of age hospitalized (admission to hospital for at least 24 h) from June 2013 to May 2018 with a microbiologically confirmed diagnosis of RVGE were selected for the analysis.
Data collection
In each hospital, the microbiology department electronic records were examined to identify all hospitalizations with a positive laboratory test for RVGE in children <5 years of age during the study period. The hospitals mainly used immunochromatography tests for RV detection, although the proportion of hospitals using immunochromatography versus molecular tests (PCR) increased from 1 out of 12 in 2013–2014 to 4 in 2017–2018.

The total number of all-cause emergency room (ER) visits or hospitalizations and the number of AGE of any etiology hospitalizations in children <5 years of age were collected from the hospital administrative database. Clinical records of patients were reviewed to collect data on the type of RVGE (community-acquired or nosocomial).

All study data were reviewed and introduced in an electronic case report form by the investigators.

Statistical analysis
For the estimation of the hospitalization ratios, sample size was determined based on the results published by Orrico-Sánchez et al. in which, with a VCR that reached up to 42.13%, the proportion of RVGE cases among all hospitalizations in children <5 years of age during the postvaccine introduction period was 1.9%. The study was performed in 20 hospitals from the Autonomous Community of Valencia over a 7-year period [15]. That represents approximately 20 RVGE hospitalizations per hospital and year. Therefore, for the present study, a convenience sample of 12 hospitals would provide a total of 1200 hospitalizations due to RVGE during the 5-year study period. This sample would allow us to estimate a proportion of 1.9% RVGE hospitalizations among all hospitalizations with a precision of 0.79% and a confidence level of 95%.

Annual hospitalization ratios were calculated according to the formula: Annual number of diagnosed RVGE hospitalizations among children <5 years of age/Total number of all-cause hospitalizations among children <5 years of age during the study period × 100.

The proportion of all-cause ER visits that were hospitalized due to any cause, AGE and RVGE among the study groups was also calculated. The number of ER visits was used as a proxy to estimate which proportion of children <5 years of age attending ER are hospitalized due to any cause, AGE and RVGE.

We calculated 95% confidence intervals (95% CIs) by assuming hospitalization rates followed a normal distribution and thus used standardized tables to estimate upper and lower bounds. Hospitalization ratios and 95% CIs for community-acquired RVGE and nosocomial RVGE separately were also calculated. For this purpose, records of a randomized sample of 1000 patients were reviewed to estimate the percentage of episodes, among the total sample, that were due to nosocomial and community-acquired infection. Nosocomial RVGE was defined as any episode of AGE appearing from at least 48 h after admission to 72 h after hospital discharge with laboratory test positive for RV infection.

The proportions of all-cause hospitalizations that were due to RVGE and AGE were compared among the three study groups, using a Chi-square or Fisher exact test, and adjusted odds ratios (ORs) with respective 95% CIs were calculated. Low VCR group was used as reference group for comparisons.

All statistical analyses were performed using SAS version 9.4. A level of statistical significance of 0,0.05 was applied to all statistical tests.

Results
Twelve hospitals (4 per VCR group) were included in the study (Fig. 1). The average estimated VCR in the low, intermediate, and high VCR groups was 21%, 47% and 69%, respectively (Additional file 1: Table S1). Aggregated pediatric population (children ≤14 years of age) of the catchment area of hospitals was 278,197 children in the low, 271,192 children in the intermediate and 234,350 children in the high VCR groups.

A total of 1,347,770 all-cause ER visits, 61,448 all-cause hospitalizations, and 3972 AGE hospitalizations of any etiology in children <5 years of age were collected during the 5-year study period. The total number of RVGE confirmed hospitalizations was 1731. The percentage of nosocomial RV infections among all RVGE-related hospitalizations was 16.47%.

Table 1 summarized the number and proportion of all-cause ER visits, all-cause hospitalizations, AGE and RVGE hospitalizations in children <5 years of age per VCR group.

The high VCR group showed the highest proportion of hospitalizations due to any cause among children attending ER but the lowest proportion of hospitalizations due to RVGE (Table 1).

The overall proportion of RVGE hospitalizations among all-cause hospitalizations in children <5 years (including community-acquired and nosocomial) was 2.82% (95% CI 2.72–3.00) and ranged from 2.38% (95% CI 2.16–2.6) to 3.21% (95% CI 2.95–3.49) in the different years included in the study period (Fig. 2). Different annual patterns can be observed in the different study groups. In the intermediate VCR group, biennial peaks are observed in the 2014–2015 and 2016–2017 seasons. A less pronounced peak is also observed during the 2016–2017 season in the high VCR group. RVGE
accounted for 43.84% (95% CI 40.53–47.21) of the total AGE hospitalizations in children <5 years of age, ranging from 40.39% (95% CI 37.33–43.51) to 49.87% (95% CI 46.83–52.91) in the study period years.

Among the study groups, the percentages of nosocomial infections were 14.07%, 20.66% and 14.67% for the low, intermediate, and high VCR groups, respectively. Community-acquired and nosocomial RVGE episodes accounted for 2.38% (95% CI 2.15–2.63) and 0.52% (95% CI 0.40–0.68), respectively, of all-cause hospitalizations in children <5 years of age during the study period and 36.85% (95% CI 33.55–40.29) and 7.73% (95% CI 5.95–9.96), respectively, of AGE hospitalizations.

Table 2 summarizes the estimated differences in the proportions of RVGE hospitalizations between study groups, considering the low VCR group as reference for comparisons. Statistically significant differences were observed in the proportion of hospitalization due to RVGE in children <5 years between study groups. Compared to the area with the lowest VCR (≤30%), the proportion of RVGE hospitalizations was 56% and 27% lower in the high and the intermediate VCR groups, respectively (Table 2).
Table 2 Proportions of all-cause hospitalizations in children < 5 years that are due to RVGE and OR (95% CI) during the study period among VCR groups

| VCR group | Proportion of hospitalizations due to RVGE % (95% CI) | OR (95% CI) |
|-----------|------------------------------------------------------|-------------|
| ≤ 30%     | 3.8 (3.71–4.27)                                      | Ref         |
| 31–59%    | 2.95 (2.71–3.22)                                     | 0.73 (0.65–0.82) |
| ≥ 60%     | 1.78 (1.62–1.95)                                     | 0.44 (0.39–0.49) |

Proportions of hospitalizations were calculated among all-cause hospitalizations in children < 5 years

VCR vaccination coverage rate, RVGE Acute Gastroenteritis due to Rotavirus, AGE Acute Gastroenteritis, OR odds ratio, 95% CI 95% confidence interval, Ref. reference group for OR calculation.

Discussion

Vaccines against RV have been shown to have an impact in reducing the hospitalizations due to RVGE in children < 5 years of age that seems to be highly dependent on the fulfilled vaccination coverage [13, 28].

We found an association between reductions in RVGE-related hospitalizations and RV VCR across all provinces studied. The greater the VCR, the larger the decline in the likelihood of RVGE hospitalizations, as showed by the 27% and 56% lower proportions of hospitalizations due to RVGE in the intermediate a high VCR group, respectively, compared to the low VCR area. Previous studies in the Valencia region have described this specific coverage-related impact on hospitalizations due to RVGE. Orrico-Sánchez et al. found an age-dependent RVGE hospitalization rate decrease of 67% to 71% with a VCR ≥ 40% compared to no vaccination. These reductions seem to be higher than those observed in our study, but it is important to note that the reference group for comparisons in our study was a low vaccination group rather than a no vaccination group; this could explain why the reductions in hospitalization ratios in our study were less pronounced. In the analysis conducted by Orrico-Sánchez, reduction in the RVGE hospitalization rate was observed in very young children even in areas with VCR of less than 20% [15]. These findings support the need to increase the vaccination coverage to maximize its clinical impact, especially on the severe burden of disease requiring hospital treatment.

The proportion of RVGE recorded as nosocomial in our study (16.5%), is consistent with the incidences reported by other authors [6, 29–31]. This may be considered of epidemiologic and clinical concern, and efforts to implement preventive measures, including vaccination, should be made.

Interestingly, hospitals in the high VCR group showed a greater proportion of pediatric all-cause hospital admissions over the total ER visits but the lowest RVGE hospitalization ratios. Considering only the time period analyzed in the study, this may suggests that the differences in the RVGE hospitalization ratios are related to the increase in the VCR for RV vaccines, regardless of the pediatric hospital admission capacity or the hospital-related criteria for admission for a given disease. More analyses, including ER visits and hospitalization data outside the vaccination period, should be performed to confirm this observation.

Another interesting finding in our study is that, the reductions in the RVGE hospitalizations seem to be stronger than the differences in the VCR between groups; For example, while the reduction in the proportion of RV hospitalization between high and low VCR groups was 57%, the difference between the average VCR between the same groups was 48%. Other authors have observed an indirect protective effect of the RV vaccination on unvaccinated individuals [32]. Anyhow, our study was not design to evaluate the indirect effects so attributing these results to herd protection should be made with caution.

During the study period, small biennial hospitalization ratios increases are observed in the intermediate and high VCR groups. This pattern has been previously reported in other countries, like the US, where vaccination coverage is suboptimal [33]. On the other hand, in Finland, in which vaccination coverage rates were over 90% since vaccine program implementation, low level of RV activity is observed with no biennial epidemics reported [34].

Our study has some limitations. First, other factors besides vaccination such as changes in the detection methods of RVGE episodes over time and differences in the admission criteria between hospitals may have contributed to the differences in hospitalization ratios observed [13]. More strict admission criteria may have contributed to the lower number of hospitalizations due to RVGE in the high VCR group, but in that case, other cause hospitalizations would have been probably lower also. Therefore, by using the total number of children < 5 years hospitalized due to any cause as denominator to calculate the hospitalization ratios minimizes the potential effect of differences in hospital admission criteria. Moreover, data aggregation from different hospitals in each study group would have also minimized the impact of individual hospital factors in the differences observed. Secondly, only hospitals with microbiological electronic records for the 5-year study period from provinces with different VCR were selected. Hence, the study population might not be entirely representative of the Spanish pediatric population. Finally, as RV vaccination is not included in the national immunizations program in
Spain, no official vaccination coverage figures are available; therefore, for the purposes of this study, the number of vaccine doses distributed and the total number of children born each year within each province was used to estimate the VCR. Observed results depend on the VCR in the years before the study. Substantial changes in the prior VCR may have an impact on hospitalization rates estimated. In Spain, since 2010 VCR has been increasing in all provinces, but changes were steady with no significant fluctuations from 1 year to another.

In contrast, strengths include the long study period, including five RV seasons, the number and diversity of participating hospitals, the large sample size included in the analysis, and the use of reliable sources of data that allow the identification of all hospitalizations due RVGE.

Conclusion

Ratios of RVGE-related hospitalizations are highly dependent on the RV VCR. Burden of hospitalizations due to RVGE is still important in Spain and may be reduced by increasing the vaccination coverage rate in areas with moderate vaccine use.

Acknowledgements

We gratefully acknowledge all site investigators of the participating hospitals for their contribution to the study: Leyre Román (Hospital Universitario 12 de Octubre), Andrea Seoane (Hospital Universitario 12 de Octubre), Isabel Gimeno (Hospital Universitario 12 de Octubre), Pilar Cedena (Hospital Universitario 12 de Octubre), Marí A Paleolae Orellana (Hospital Universitario 12 de Octubre), Bávara Calero (Hospital Clínico Universitario Virgen de la Arrixaca), Raúl Morcillo (Hospital Clínico Universitario Virgen de la Arrixaca), Paula Vidal (Hospital Regional de Málaga), Jaime Gutierrez (Hospital Regional Universitario de Málaga), Elisa Garrote (Hospital Universitario de Basurto), Elia Doménech (Hospital Germans Trias i Pujol), Emilio Monteagudo (Hospital La Fe), Laura Pérez (Hospital La Fe), Carlos Ortiz (Hospital Universitario y Politécnico La Fe), Gustavo Cilla (Hospital Universitario de Donostia), Miriam Alkorta (Hospital Universitario de Donostia), Marta Illan (Hospital Universitario Clínico San Carlos), Claudia García (Hospital Juan Ramón Jiménez), Pedro Márquez (Hospital Juan Ramón Jiménez), Mónica Frutos (Hospital Universitario Río Hortega), Carlos Alcalde (Hospital Universitario Río Hortega), Marina G. Sánchez (Hospital Universitario Río Hortega), Lucía Palacios (Hospital Universitario Río Hortega), Rosalia Cebrián (Hospital Universitario Río Hortega), Ana Isabel Elola (Hospital Universitario Central de Asturias), Alicia Pérez (Hospital Universitario Central de Asturias), María Angustias Alvarez (Hospital Universitario Central de Asturias),

Authors' contributions

JRC, MMH, JTRA, JA, MC, and MSM contributed to the study design. JRC, MMH, JTRA, JA and MSM participated in the analysis of data and drafted the manuscript. JRC, SAM, BCG, EO, LDM, MM, MMH, BFL, MUM, JTRA, BCS, FCM and JRS contributed to the acquisition of data. All authors were involved in the critical review and revising of the final manuscript. All authors read and approved the final manuscript.

Funding

This study was funded by MSD Spain, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was designed, conducted and reported in accordance with the Guidelines for Good Pharmacoepidemiology Practices of the International Society for Pharmacoepidemiology, with the ethical principles of the Declaration of Helsinki, and with the current Spanish legislation related to observational studies (Ministral Order SAS/3470/2009). The study was reviewed and approved by the Clinical Research Ethics Committee of the Basque Country in Txagorritxu Hospital (Vitoria, Spain). This Committee was the reference Ethics Committee for the study coordinator hospital (Hospital de Basurto).

According to the Guidelines for Good Pharmacoepidemiology Practices and the Spanish regulation for non-interventional observational studies using secondary data sources in which a procedure for de-identification of data is implemented, there is no need for subject informed consent collection. In the present study, only already existing data from databases and clinical records was collected, there was no interview with subjects, and all data was securely and adequately dissociated. The Ethics Committee of the Basque Country in Txagorritxu Hospital (Vitoria, Spain) approved this informed consent waiver.

Consent for publication

Not applicable.

Competing interests

MC, and MSM are employees of MSD Spain. All other authors do not have any competing interest.

Author details

1Pediátricos, Hospital Universitario 12 de Octubre, Madrid, Spain. 2Pediátricos, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. 3Pediátricos, Hospital Regional Universitario de Málaga, Málaga, Spain. 4Pediátricos, Hospital Universitario de Basurto, Bilbao, Spain. 5Pediátricos, Complejo Hospitalario de Navarra, Pamplona, Spain. 6Pediátricos, Hospital Germans Trias i Pujol, Badalona, Spain. 7Pediátricos, Hospital Universitario y Politécnico La Fe, Valencia, Spain. 8Pediátricos, Hospital Universitario de Donostia, San Sebastián, Spain. 9Pediátricos, Hospital Universitario Clínico San Carlos, Madrid, Spain. 10Pediátricos, Hospital Juan Ramón Jiménez, Huelva, Spain. 11Pediátricos, Hospital Universitario Río Hortega, Valladolid, Spain. 12Pediátricos, Hospital Universitario Central de Asturias, Oviedo, Spain. 13Medical Affairs Department, MSD Spain. C/ Josefa Valcárcel, 38, 28027 Madrid, Spain.

Received: 12 May 2021 Accepted: 29 October 2021

Published online: 06 November 2021

References

1. Crawford SE, Ramani S, Tate JE, Parashar UD, Svensson L, Hagborg M, et al. Rotavirus infection. Nat Rev Dis Primers. 2017;3:17083. https://doi.org/10.1038/nrdp.2017.83.
2. ECDC. Expert opinion on rotavirus vaccination in infancy. 2017. https://www.ecdc.europa.eu/en/publications-data/expert-opinion-rotavirus-vaccination-infancy.
3. Aristegui J, Ferrer J, Salamanca I, Garrote E, Partidas A, San-Martin M, et al. Multicenter prospective study on the burden of rotavirus gastroenteritis.
in children less than 3 years of age in Spain. BMC Infect Dis. 2016;16:549.
https://doi.org/10.1186/s12879-016-1890-7.

4. Pediatric ROTavirus European Committee. The paediatric burden of rotavirus disease in Europe. Epidemiol Infect. 2006;134:908–16. https://doi.org/10.1017/S0950268806006091.

5. Van Damme P, Giaquinto C, Huet F, Goethals L, Maxwell M, Van der Wielen M, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004–2005: the REVEAL study. J Infect Dis. 2007;195:54–16. https://doi.org/10.1086/516714.

6. Glezes O, Desselberger U, Tatochenko V, Rodrigo C, Salman N, Mezner Z, et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediafr Infect Dis J. 2006;25:12–21. https://doi.org/10.1097/01.inf.0000197563.03895.91.

7. Karafillakis E, Hassounah S, Atchison C. Effectiveness and impact of rotavirus vaccines in Europe, 2006–2014. Vaccine. 2015;33:2097–107. https://doi.org/10.1016/j.vaccine.2015.03.016.

8. Jonesteller CL, Burnett E, Yen C, Tate JE, Parashar UD. Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006–2016. Clin Infect Dis. 2017;65:840–50. https://doi.org/10.1093/cid/cix369.

9. de Hoog MLA, Vesikari T, Giaquinto C, Huppertz H, Martinon-Torres F, Bruinjung-Verhagen P. Report of the 5th European expert meeting on rotavirus vaccination (EEROVAC). Hum Vacc Immunother. 2018;14:1027–34. https://doi.org/10.1080/21645515.2017.1412019.

10. Hartwig S, Uhan M, Renko M, Bertet P, Hemming M, Vesikari T. Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with Rotarix®. BMC Health Serv Res. 2014;14:632.

11. Rotarix SMPC. https://www.ema.europa.eu/en/documents/product-information/rotarix-epar-product-information_en.pdf.

12. Rotarix SMPC. https://www.ema.europa.eu/en/documents/product-information/rotarix-epar-product-information_en.pdf.

13. Diez-Domingo J, Garces-Sanchez M, Gimenez-Sanchez F, Colomina-Rodriguez J, Martinon-Torres F. What have we learnt about rotavirus in Spain in the last 10 years? An Pediatr (Barc). 2019;91:166–79. https://doi.org/10.1016/j.anpedi.2019.01.024.

14. Perez-Ortin R, Santos-Bello C, Vila-Vicent S, Carmona-Vicente N, Rodriguez-Diaz J, Buesa J. Rotavirus symptomatic infection among unvaccinated and vaccinated children in Valencia, Spain. BMC Infect Dis. 2019;19:998. https://doi.org/10.1186/s12879-019-4550-x.

15. Orrico-Sanchez A, Lopez-Lacort M, Perez-Vilar S, Diez-Domingo J. Long-term impact of self-funded rotavirus vaccines on rotavirus-associated hospitalizations and costs in the Valencia Region, Spain. BMC Infect Dis. 2017;17:267. https://doi.org/10.1186/s12879-017-2380-2.

16. Gil-Prieto R, Gonzalez-Escalada A, Alvaro-Meca A, Garcia-Garcia L, San-Martin M, Gonzalez-Lopez A, et al. Impact of non-routine rotavirus vaccination on diarrhoea and rotavirus infections in Spain. Vaccine. 2013;31:5000–4. https://doi.org/10.1016/j.vaccine.2013.05.109.

17. Martinon-Torres F, Martinon-Torres N, Bouzon Alejandro M, Redondo Collazo L, Pertega-Diaz S, Seoane-Pillado MT, et al. Acute gastroenteritis hospitalizations among children aged < 5 years before and after introduction of rotavirus vaccines: a hospital-based surveillance study in Galicia, Spain. Hum Vaccines Immunother. 2012;8:946–52. https://doi.org/10.4161/hv.20178.

18. Redondo O, Cano R, Simon L. Decline in rotavirus hospitalizations following the first three years of vaccination in Castile-La Mancha, Spain. Hum Vaccines Immunother. 2015;11:769–75. https://doi.org/10.4161/2165515.2015.1009339.

19. Martinon-Torres F, Aramburo A, Martinon-Torres N, Cebey M, Seoane-Pillado MT, Redondo-Collazo L, et al. A reverse evidence of rotavirus vaccines impact. Hum Vaccin Immunother. 2013;9:1289–91. https://doi.org/10.4161/hv.24182.

20. Cilla G, Gomariz M, Montes M, Mendiburu MI, Perez-Yarza EG, Perez-Trallero E. Incidence of hospitalization due to community-acquired rotavirus infection: a 12-year study (1996–2008). Epidemiol Infect. 2010;138:1235–41. https://doi.org/10.1017/S095026881000004X.

21. Garcia-Basteiro AL, Bosch A, Scutari E, Bayas JM, Trilla A, Hayes EB. Hospitalizations due to rotavirus gastroenteritis in Catalonia, Spain, 2003–2008. BMC Res Notes. 2011;4:429. https://doi.org/10.1186/1756-0500-4-429.

22. Gil A, Carrasco P, Jimenez R, San-Martin M, Oyaguez I, Gonzalez A. Burden of hospitalizations attributable to rotavirus infection in children in Spain, period 1999–2000. Vaccine. 2004;22:2221–5. https://doi.org/10.1016/j.vaccine.2003.11.037.

23. Lopez-de-Andres A, Jimenez-Garcia R, Carrasco-Garrido P, Alvaro-Meca A, Galarza PG, de Miguel AG. Hospitalizations associated with rotavirus gastroenteritis in Spain, 2001–2005. BMC Public Health. 2008;8:109. https://doi.org/10.1186/1471-2458-8-109.

24. Luqueiro FJ, Hernan Garcia C, Eiros Bouza JM, Castrodeza Sanz J, Sanchez-Padilla E, Simon Sorfa E, et al. Profile of paediatric admissions and emergencies during an epidemic period of rotavirus in Valladolid [Spain]. Utility of a predictive model. Gac Sanit. 2009;23:58–61. https://doi.org/10.1016/j.gaceta.2008.03.004.

25. Hsu VP, Staat MA, Roberts N, Thierman C, Bernstein DI, Bresee J, et al. Use of active surveillance to validate international classification of diseases code estimates of rotavirus hospitalizations in children. Pediatrics. 2005;115:78–82. https://doi.org/10.1542/peds.2004-0860.

26. Guidelines for Good Pharmacoeconomics Practices (GPP). 2015. https://www.pharmacoepi.org/resources/policies/guidelines-08027/.

27. Ministerial order SAS/3470/2009. https://www.aemps.gob.es/legislacion/espana/medicamentos/usoHumano/docs/farmacovigilancia/crl_2009_2577.pdf.

28. Gilbueva‑Gimeno MV, Martin‑Moreno JM, Diez‑Domingo J, Asensi‑Botet F, Hernandez‑Marco R, Correcher‑Medina F, et al. Nosocomial rotavirus gastroenteritis in Spain: a multicenter prospective study. Pediatr Infect Dis J. 2010;29:23–7. https://doi.org/10.1097/INF.0b013e3181b3603a.

29. Gervasi G, Capanna A, Mita V, Zaratti L, Franco E. Nosocomial rotavirus infection: an up to date evaluation of European studies. Hum Vaccines Immunother. 2016;12:2413–8. https://doi.org/10.4161/hv.201854515.2016.1013858.

30. Ogilvie I, Khoury H, Goetgebeur MM, El Khoury AC, Giaquinto C. Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis. 2012;12:62. https://doi.org/10.1186/1471-2334-12-62.

31. Rossette KL, Vos T, Mokdad AH, Flaxman AD, Khalil I, Troeger C, et al. Indirect rotavirus vaccine effectiveness for the prevention of rotavirus hospitalization: a systematic review and meta-analysis. Am J Trop Med Hyg. 2018;98:1197–201. https://doi.org/10.4269/ajtmh.17-0705.

32. Baker JM, Tate JE, Steiner CA, Haber MJ, Parashar UD, Lopman BA. Longer-term direct and indirect effects of infants rotavirus vaccination across all ages in the United States in 2000–2013: analysis of a large hospital discharge data set. Clin Infect Dis. 2019;68(6):976–83. https://doi.org/10.4161/hv.24182.